FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2549665890> ?p ?o ?g. }

• W2549665890 abstract "Abstract Abstract 14 High dose chemotherapy followed by autologous blood and marrow transplantation (ABMT) has been used to treat patients with acute myeloid leukemia (AML), but leukemia relapse rates remain high. One reason is the potential contamination of marrow with leukemic stem and progenitor cells (LSPCs). Purging autologous hematopoietic grafts of LSPCs prior to transplant serves as a viable strategy for increasing transplant efficacy in these cases; however, previous attempts using cytotoxic agents and cell culture techniques have generally resulted in loss of normal stem and progenitor cell numbers and/or functionality. Oncolytic poxviruses, such as myxoma virus (MYXV), are promising new instruments in targeting human cancer. MYXV has normal tropism towards European rabbits (Oryctolagus cuniculus) while remaining nonpathogenic for all other vertebrate species tested including humans and mice. Despite this host specificity, we have shown that MYXV is capable of infecting and killing a wide variety of human cancer cell lines. In light of these observations, we investigated whether MYXV could specifically target and eliminate LSPCs from primary AML using an ex vivo purging technique as assessed using both in vitro and in vivo functional analyses. Using a MYXV construct that expresses GFP upon cell infection, we observed GFP+ cells in leukemia exposed to MYXV at a concentration of 10 MOI over a 3-day period. No GFP expression was observed in normal bone marrow (BM) or mock (vehicle only) treated controls. GFP+ AML cells also began to undergo apoptosis shown by positive Annexin V staining. For myxoma to be a viable therapeutic for leukemia, it must not only target primary leukemia but also spare normal hematopoietic stem and progenitor cells (HSPCs). To test normal progenitor cell function following exposure to MYXV, normal BM cells were incubated with and without MYXV and tested for colony forming cell (CFC) content. Following incubation with MYXV, we observed differentiated colonies forming after 14 days indicating that the CFC potential of normal HSPCs was not adversely affected by MYXV. The frequency of the different colonies formed was also similar between mock and MYXV treated groups. When AML cells were mock treated pleomorphic colonies formed consistent with AML-colony forming units (AML-CFUs). Conversely, when exposed to MYXV, AML cells did not form recognizable AML-CFU colonies and instead remained heterodispersed suggesting impairment of progenitor cell function in vitro. To assess functional effects of MYXV on leukemia engraftment, sublethally irradiated NOG mice were transplanted with either mock treated primary AML (n=7) or primary AML pre-treated with MYXV for 3 hours (n=10). After 8 weeks, the percentage of engrafted mice was 100% after mock treated AML transplant but dropped to 10% after MYXV treatment. Significantly lower mean engraftment was observed in the group that received MYXV treated AML in comparison to mock treated samples (4.5% vs. 24% respectively; p < 0.05). Moreover, we show susceptibility of a primary AML specimen harboring an activating internal tandem duplication (ITD) mutation in FLT3, which represents an aggressive malignancy well-known for insensitivity to conventional chemotherapy. In animals showing leukemia engraftment by FACS, PCR was positive for the FLT3 ITD mutation. However, molecular remissions were evident in mice receiving MYXV treated samples. Efficacy against this leukemia signifies opportunity for disease eradication in an otherwise grim clinical setting. Finally, to assess functional effects of MYXV on normal HSPC engraftment, sublethally irradiated NOG mice were transplanted with either mock treated normal BM (n=10) or MYXV treated BM (n=9). After 8 weeks, there was no difference in the numbers of mice that engrafted between mock treated or MYXV treated groups (70% vs. 78% respectively; p = 0.72). There was also no difference in mean levels of engraftment per animal (1% vs. 2%; p = 0.41) suggesting that MYXV does not adversely affect the in vivo engraftment potential of normal HSPCs. In these studies, primary human LSPCs were targeted by MYXV purging, while normal human HSPCs showed no response maintaining both in vitro and in vivo functional potential. Given this demonstrated efficacy and safety, ex vivo purging of autologous hematopoietic grafts with MYXV may be feasible in cancer patients undergoing high dose chemotherapy followed by ABMT. Disclosures: No relevant conflicts of interest to declare." @default.
• W2549665890 created "2016-11-30" @default.
• W2549665890 creator A5034744182 @default.
• W2549665890 creator A5035200799 @default.
• W2549665890 creator A5035318635 @default.
• W2549665890 creator A5042492175 @default.
• W2549665890 creator A5079972284 @default.
• W2549665890 creator A5087667645 @default.
• W2549665890 date "2009-11-20" @default.
• W2549665890 modified "2023-10-01" @default.
• W2549665890 title "Myxoma Virus Targets Primary Human Leukemic Stem and Progenitor Cells While Sparing Normal Hematopoietic Stem and Progenitor Cells." @default.
• W2549665890 doi "https://doi.org/10.1182/blood.v114.22.14.14" @default.
• W2549665890 hasPublicationYear "2009" @default.
• W2549665890 type Work @default.
• W2549665890 sameAs 2549665890 @default.
• W2549665890 citedByCount "2" @default.
• W2549665890 countsByYear W25496658902013 @default.
• W2549665890 countsByYear W25496658902016 @default.
• W2549665890 crossrefType "journal-article" @default.
• W2549665890 hasAuthorship W2549665890A5034744182 @default.
• W2549665890 hasAuthorship W2549665890A5035200799 @default.
• W2549665890 hasAuthorship W2549665890A5035318635 @default.
• W2549665890 hasAuthorship W2549665890A5042492175 @default.
• W2549665890 hasAuthorship W2549665890A5079972284 @default.
• W2549665890 hasAuthorship W2549665890A5087667645 @default.
• W2549665890 hasConcept C10205521 @default.
• W2549665890 hasConcept C109159458 @default.
• W2549665890 hasConcept C126322002 @default.
• W2549665890 hasConcept C150903083 @default.
• W2549665890 hasConcept C201750760 @default.
• W2549665890 hasConcept C203014093 @default.
• W2549665890 hasConcept C207001950 @default.
• W2549665890 hasConcept C2522874641 @default.
• W2549665890 hasConcept C26291073 @default.
• W2549665890 hasConcept C2778461978 @default.
• W2549665890 hasConcept C2778729363 @default.
• W2549665890 hasConcept C2779745803 @default.
• W2549665890 hasConcept C28328180 @default.
• W2549665890 hasConcept C2911091166 @default.
• W2549665890 hasConcept C502942594 @default.
• W2549665890 hasConcept C71924100 @default.
• W2549665890 hasConcept C82210918 @default.
• W2549665890 hasConcept C86803240 @default.
• W2549665890 hasConcept C95444343 @default.
• W2549665890 hasConceptScore W2549665890C10205521 @default.
• W2549665890 hasConceptScore W2549665890C109159458 @default.
• W2549665890 hasConceptScore W2549665890C126322002 @default.
• W2549665890 hasConceptScore W2549665890C150903083 @default.
• W2549665890 hasConceptScore W2549665890C201750760 @default.
• W2549665890 hasConceptScore W2549665890C203014093 @default.
• W2549665890 hasConceptScore W2549665890C207001950 @default.
• W2549665890 hasConceptScore W2549665890C2522874641 @default.
• W2549665890 hasConceptScore W2549665890C26291073 @default.
• W2549665890 hasConceptScore W2549665890C2778461978 @default.
• W2549665890 hasConceptScore W2549665890C2778729363 @default.
• W2549665890 hasConceptScore W2549665890C2779745803 @default.
• W2549665890 hasConceptScore W2549665890C28328180 @default.
• W2549665890 hasConceptScore W2549665890C2911091166 @default.
• W2549665890 hasConceptScore W2549665890C502942594 @default.
• W2549665890 hasConceptScore W2549665890C71924100 @default.
• W2549665890 hasConceptScore W2549665890C82210918 @default.
• W2549665890 hasConceptScore W2549665890C86803240 @default.
• W2549665890 hasConceptScore W2549665890C95444343 @default.
• W2549665890 hasLocation W25496658901 @default.
• W2549665890 hasOpenAccess W2549665890 @default.
• W2549665890 hasPrimaryLocation W25496658901 @default.
• W2549665890 hasRelatedWork W1003148605 @default.
• W2549665890 hasRelatedWork W115453787 @default.
• W2549665890 hasRelatedWork W133590584 @default.
• W2549665890 hasRelatedWork W185812665 @default.
• W2549665890 hasRelatedWork W2029202541 @default.
• W2549665890 hasRelatedWork W2054832035 @default.
• W2549665890 hasRelatedWork W2058094297 @default.
• W2549665890 hasRelatedWork W2069025933 @default.
• W2549665890 hasRelatedWork W2070819167 @default.
• W2549665890 hasRelatedWork W2091245878 @default.
• W2549665890 hasRelatedWork W2121648706 @default.
• W2549665890 hasRelatedWork W2174920394 @default.
• W2549665890 hasRelatedWork W2412633362 @default.
• W2549665890 hasRelatedWork W2414703178 @default.
• W2549665890 hasRelatedWork W2553702429 @default.
• W2549665890 hasRelatedWork W2555158278 @default.
• W2549665890 hasRelatedWork W2571777407 @default.
• W2549665890 hasRelatedWork W2576029558 @default.
• W2549665890 hasRelatedWork W2906574398 @default.
• W2549665890 hasRelatedWork W2980039019 @default.
• W2549665890 isParatext "false" @default.
• W2549665890 isRetracted "false" @default.
• W2549665890 magId "2549665890" @default.
• W2549665890 workType "article" @default.